Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "8098", "attributes": { "award_id": "75N92021C00003-0-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROJECT #6139: REVOGENE SARS-COV-2 ASSAY", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-01", "end_date": "2022-01-31", "award_amount": 5505000, "principal_investigator": { "id": 23980, "first_name": "TODD", "last_name": "WOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Resubmission of Application 3136. This product concept has been updated to include Flu viral targets along with SARS-CoV-2. The Rapid Acute Respiratory Panel assay will be a molecular IVD assay practiced on an already deployed automated Revogene instrument which currently has 4 infectious disease FDA cleared assays. The intended use will be to detect the Flu A, Flu B and SARS-CoV-2 viruses from nasopharyngeal specimens collected from symptomatic patients suspected of viral infection. This will be a multiplexed viral panel for the differentiation of Flu from SARS-CoV-2 patients which will be of high clinical value in our upcoming Flu season 2020-2021. We plan to launch this assay with EUA status by October 2020. The assay will detect RNA sequences for these viral targets using PCR amplification technology coupled with real-time flourescence detection similar to our FDA cleared assays. The workflow is automated where the user will need to add the specimen to the assay consumable prior to loading on the instrument. The Revogene platform contains the necessary software to run the assay and report out positive/negative results. This assay is of very low complexity to practice with no precision pipetting steps and is eligible for CLIA waiver status. We currently have an installment base of instruments in the field where this assay will be practiced. For this product concept, we will need your assistance in discussing this concept with the FDA to allow us to gain EUA and CLIA waiver status especially for the Flu A/B targets in the panel.", "keywords": [ "2019-nCoV", "Acute", "Biological Assay", "COVID-19 assay", "COVID-19 patient", "Clinical", "Communicable Diseases", "Computer software", "Coupled", "Detection", "Molecular", "Patients", "RADx Tech", "RNA Sequences", "Reporting", "Running", "Seasons", "Specimen", "Technology", "Time", "Update", "Viral", "Virus", "Virus Diseases", "base", "betacoronavirus", "flu", "instrument", "respiratory", "waiver" ], "approved": true } }, { "type": "Grant", "id": "5124", "attributes": { "award_id": "NNX10AR42G", "title": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2011-01-01", "end_date": "2012-12-31", "award_amount": 0, "principal_investigator": { "id": 18257, "first_name": "DAVID", "last_name": "BUOTE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1407, "ror": "", "name": "REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (6406)", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": null, "abstract": "We propose a set of two 19 arcmin offset observations for the galaxy group MKW 4 to measure spatially resolved density, temperature and iron abundance out to 1''500, These measurements are crucial for an accurate determination of the gas mass profile and", "keywords": [], "approved": true } }, { "type": "Grant", "id": "4102", "attributes": { "award_id": "NNX16AK48G", "title": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2016-05-23", "end_date": "2017-05-22", "award_amount": 0, "principal_investigator": { "id": 13774, "first_name": "CYRENA", "last_name": "GOODRICH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "ASTEROID 2008 TC3 WAS TRACKED AND STUDIED IN SPACE FOR ~19 HOURS BEFORE IT IMPACTED EARTH'S ATMOSPHERE AND SHATTERED OVER NORTHERN SUDAN ON OCTOBER 7, 2008.WE WILL CONDUCT PETROLOGIC STUDIES, OXYGEN ISOTOPE ANALYSES, AR-AR DATING, AND SPECTROSCOPIC MEASUR", "keywords": [], "approved": true } }, { "type": "Grant", "id": "13498", "attributes": { "award_id": "75N95020D00011-0-759502300002-1", "title": "NCATS CYBERSECURITY SERVICES DIVISION PROGRAM SUPPORT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-29", "end_date": "2024-02-28", "award_amount": 1427260, "principal_investigator": { "id": 29624, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides IT security support for all of these enterprise IT efforts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8222", "attributes": { "award_id": "75N92021C00008-0-9999-1", "title": "AWARD A CONTRACT FOR RADX TECH - QORVO TO SECURE AN EUA APPROVED POC ANTIGEN TEST SYSTEM AS WELL AS INCREASE AN INCREMENTAL DAILY CARTRIDGE PRODUCTION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-02", "end_date": "2022-04-01", "award_amount": 24361759, "principal_investigator": { "id": 24054, "first_name": "HANJOON", "last_name": "RYU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving confidence in POC tests. Developed over a 6+ year timeframe, the technological differentiation is in the detection core, where Qorvo has optimized the BAW device that is made at low cost and high volume (millions per day for cell phones) for liquid biosensing. Detection of SARS-CoV-2 antigen occurs with a shift in the biosensor resonance frequency as antigen (Nucleocapsid and Spike S1) protein mass accumulates at specific probes on the sensor surface. Traditional optical/ fluorescence sensing is replaced by high-sensitivity, high-specificity solid-state mass-based sensing. While this proposal is focused on antigen test development, Qorvo has submitted for a SARS-CoV-2 IgG antibody test EUA on the same BAW platform that was completed in less than 10 weeks with world-class performance of 100% specificity and 100% negative cross reactivity. Given this is just one of over a dozen other assays previously run through this platform, the results give us extreme confidence in our ability to execute the viral antigen technical and timeline tasks. Qorvo has invested heavily in manufacturing infrastructure commercial development for the antibody test as well as existing veterinary and human development products so the antigen will be part of a product suite. RADx assistance will enable acceleration of regulatory and US-based high-volume manufacturing ramp.", "keywords": [ "2019-nCoV", "Acceleration", "Acoustics", "Antigens", "Biological Assay", "Biosensing Techniques", "Biosensor", "Cellular Phone", "Contracts", "Detection", "Development", "Devices", "Fluorescence", "Frequencies", "Human Development", "Immunoglobulin G", "Infrastructure", "Investigation", "Liquid substance", "Nucleocapsid", "Optics", "Performance", "Production", "Proteins", "RADx", "RADx Tech", "Ramp", "Running", "SARS-CoV-2 antigen", "Secure", "Specificity", "Surface", "System", "TimeLine", "Viral Antigens", "antibody test", "antigen test", "base", "cost", "cross reactivity", "design", "detection platform", "improved", "point of care", "point of care testing", "product development", "sensor", "solid state" ], "approved": true } }, { "type": "Grant", "id": "9280", "attributes": { "award_id": "75N91020C00035-0-9999-1", "title": "DIGITAL HEALTH SOLUTIONS FOR COVID-19: CLEAR2GO", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-14", "end_date": "2020-11-27", "award_amount": 274880, "principal_investigator": { "id": 25020, "first_name": "ADARBAD", "last_name": "MASTER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1816, "ror": "", "name": "ICRYPTO, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": null, "abstract": "The goal of this project is to develop a smartphone-based platform to provide irrefutable proof of testing, serologic, and vaccination status for individuals. The customized solution, called Clear2Go (C2G), maps a person’s vetted identity and biometrics to their phone and then cryptographically binds it with their COVID-19 test results or other personal health information. C2G is intended to provide individuals, employers, government agencies, and other organizations with a convenient solution to evaluate the risks associated with an individual’s return to normal work, travel, and public life activities. The aims of this project include creating the C2G solution, demonstrating that C2G can be integrated with the publicly available interface of a test laboratory portal, and conveying simulated COVID-19 test results into the C2G application. Data collected under this project will be deidentified and securely transmitted to an NIH data hub.", "keywords": [ "Binding", "Biometry", "COVID-19", "Cellular Phone", "Custom", "Data", "Goals", "Government Agencies", "Health", "Individual", "Laboratories", "Life", "Maps", "Persons", "Risk", "Secure", "Serological", "Telephone", "Test Result", "Testing", "Travel", "United States National Institutes of Health", "Vaccination", "Work", "base", "cryptography", "data hub", "digital" ], "approved": true } }, { "type": "Grant", "id": "9226", "attributes": { "award_id": "75N92020C00034-P00001-9999-1", "title": "RADX-TECH - ELLUME USA, LLC COVID-19 ANTIGEN TEST FOR THE DIRECT DETECTION OF THE SARS COV-2 VIRUS.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-30", "end_date": "2021-09-29", "award_amount": 21470000, "principal_investigator": { "id": 24967, "first_name": "SCOTT", "last_name": "FRY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "A point-of-care, in vitro diagnostic test for the detection of an acute COVID 19 infection for use by healthcare professionals. The test will detect the nucleoprotein antigen of the SARS-CoV-2 virus from a healthcare provider-collected mid-turbinate nasal swab using a hand-held digital platform. The test system is connected to a cloud platform to provide real time access to patient test results by public health authorities for surveillance and monitoring. The test system includes: 1) a single-use test cartridge that connects to the hand-held digital platform 2) a sample collection and processing device 3) a squeezable vial containing a fixed volume of extraction fluid 4) ellume.lab, a hand-held digital platform designed to display test results and provide connectivity to Ellume's cloud. 5) a cloud database and interface for real time data collection, analytics and sharing The test is based on Ellume's established fluorescent immunoassay cartridge with digital detection technology, and leverages a proprietary fluorescence biosensor, with a light signature produced by quantum dot nanoparticles detected and digitized by a highly sensitive but fully disposable optoelectronics package. Ellume.lab, Ellume's digital platform, is a hand-held smart device that can read 2 test cartridges at a time. The device provides a digital user interface and includes step-by-step test instructions, digital interpretation of test results, and is connected to Ellume's cloud platform. The device also connects to the clinic's electronic medical record (EMR) system. The device requires no calibration or maintenance, and is battery operated with over 24 hours use before requiring charging.", "keywords": [ "Acute", "Biosensor", "COVID-19 detection", "Calibration", "Charge", "Clinic", "Computerized Medical Record", "Data Collection", "Databases", "Detection", "Devices", "Fluorescence", "Hand", "Health Personnel", "Health Professional", "Hour", "Immunoassay", "Instruction", "Light", "Liquid substance", "Maintenance", "Monitor", "Nasal turbinate bone structure", "Nucleoproteins", "Patients", "Public Health", "Quantum Dots", "RADx Tech", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Step Tests", "System", "Technology", "Test Result", "Testing", "Time", "Vial device", "Virus", "antigen test", "authority", "base", "cloud platform", "design", "detection test", "digital", "in-vitro diagnostics", "nanoparticle", "nasal swab", "point of care", "sample collection" ], "approved": true } }, { "type": "Grant", "id": "10379", "attributes": { "award_id": "75N93022C00044-0-9999-1", "title": "SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2024-09-29", "award_amount": 596519, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The hamster is a well-established model for several infectious diseases including influenza and SARS-CoV-2. Lack of hamster reagents has hampered pre-clinical studies of viral pathogenesis, host immunity, and vaccine development. The objectives of this proposal are to produce and test monoclonal antibodies against 10 cytokines and chemokines and 4 T cell surface markers for characterizing cytokine responses and examining T cells activation in the hamster models of respiratory infections. Completion of this project will provide high-affinity monoclonal antibodies that allow investigators to distinguish innate and adaptive inflammatory cytokine and chemokine responses as well as activated T cells, memory T cells, tissue resident memory T cells, and regulatory T cells in the hamster models of infectious diseases.", "keywords": [ "2019-nCoV", "Affinity", "Cell surface", "Cells", "Communicable Diseases", "Generations", "Hamsters", "Immunity", "Immunization", "Immunologics", "Inflammatory", "Influenza", "Memory", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinant Proteins", "Recombinants", "Regulatory T-Lymphocyte", "Research Personnel", "Respiratory Tract Infections", "Serum", "Small Business Innovation Research Grant", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "Testing", "Tissue Sample", "Tissues", "Validation", "Viral Pathogenesis", "chemokine", "cytokine", "infectious disease model", "preclinical study", "response", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "11681", "attributes": { "award_id": "1U01DA057849-01", "title": "Supported employment to create a community culture of SARS-CoV-2 rapid testing among people who inject drugs: PeerConnect2Test", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": null, "end_date": null, "award_amount": null, "principal_investigator": { "id": 26966, "first_name": "Camille C", "last_name": "Cioffi", "orcid": "https://orcid.org/0000-0003-2424-7473", "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "['psi.uoregon.edu']", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5334", "attributes": { "award_id": "NNX08AX76G", "title": "\"THE XMM-LSS SURVEY: RE-OBSERVATION OF A05 POINTINGS AFFECTED BY RADIATION\" We propose to re-observe 19 XMM-LSS AOS fields significantly affected by radiation during A05 operations. They are part of the XMM Large Programme dedicated to full coverage of th", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2008-07-23", "end_date": "2010-09-29", "award_amount": 0, "principal_investigator": { "id": 18724, "first_name": "CAROL", "last_name": "LONSDALE", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "\"THE XMM-LSS SURVEY: RE-OBSERVATION OF A05 POINTINGS AFFECTED BY RADIATION\" We propose to re-observe 19 XMM-LSS AOS fields significantly affected by radiation during A05 operations. They are part of the XMM Large Programme dedicated to full coverage of th", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1405, "count": 14046 } } }